Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
- Conditions
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT04949191
- Locations
- 🇺🇸
Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States
🇺🇸Oncology Specialists of Charlotte, Charlotte, North Carolina, United States
🇮🇹Istituto Nazionale Tumori Regina Elena Irccs, Rome, Italy
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT04921969
- Locations
- 🇺🇸
Ohio Pediatric Research Association, Dayton, Ohio, United States
🇺🇸Velocity Clinical Research Grants Pass Clinical Research Institute of Southern Oregon Pc, Grants Pass, Oregon, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT04896385
- Locations
- 🇺🇸
George Washington Medical Faculty Associates, Washington, District of Columbia, United States
🇺🇸Suny Downstate Medical Center, Brooklyn, New York, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04849715
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 49
- Registration Number
- NCT04839380
- Locations
- 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
🇨🇦Innovoderm Research, Montreal, Quebec, Canada
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT04831996
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami, Hialeah, Florida, United States
🇺🇸Prism Research, Saint Paul, Minnesota, United States
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT04831944
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 899
- Registration Number
- NCT04824092
- Locations
- 🇨🇳
Morphsys Research Site, Taoyuan, Taiwan
🇬🇧MorphoSys Research Site, Wolverhampton, United Kingdom
🇷🇺Morphosys research site, UFA, Russian Federation
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 171
- Registration Number
- NCT04818346
- Locations
- 🇺🇸
Investigative Site 027, Verona, New Jersey, United States
🇺🇸Investigative Site 011, West Palm Beach, Florida, United States
🇺🇸Investigative Site 024, Covington, Louisiana, United States
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT04809467
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States
🇺🇸Ohio State University, Columbus, Ohio, United States